interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Empagliflozin; Linagliptin

Generic competition · all medicines · read 12 November 2026

Is there a generic of Empagliflozin; Linagliptin, and who makes it?

Empagliflozin; Linagliptin appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Empagliflozin; Linagliptin1 dosage-form group in the Orange Book
0generic makers listed
  1. Empagliflozin; Linagliptin appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Glyxambi. No generic is listed as marketed.

20152020202520302035204001brand 2015data datePatent 7713938 listed to expire 15 April 2027Patent 11033552 listed to expire 4 May 2027Patent 12178819 listed to expire 4 May 2027Patent 7713938*PED listed to expire 15 October 2027Patent 8673927*PED listed to expire 4 November 2027Patent 11033552*PED listed to expire 4 November 2027Patent 7579449 listed to expire 1 August 2028Patent 7579449*PED listed to expire 1 February 2029Patent 8551957 listed to expire 14 October 2029Patent 12115179 listed to expire 11 February 2030Patent 8551957*PED listed to expire 14 April 2030Patent 12115179*PED listed to expire 11 August 2030Patent 10258637 listed to expire 3 April 2034Patent 12433906 listed to expire 3 April 2034Patent 11090323 listed to expire 3 April 2034Patent 11833166 listed to expire 3 April 2034Patent 9949998 listed to expire 11 June 2034Patent 10258637*PED listed to expire 3 October 2034Patent 12433906*PED listed to expire 3 October 2034Patent 11833166*PED listed to expire 3 October 2034Patent 11090323*PED listed to expire 3 October 2034Patent 12364700 listed to expire 8 June 2037Patent 12364700*PED listed to expire 8 December 2037
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 15 April 2027Patent 7713938 drug substance
  • 4 May 2027Patent 11033552 drug product
  • 4 May 2027Patent 12178819 drug product
  • 15 October 2027Patent 7713938*PED
  • 4 November 2027Patent 8673927*PED
  • 4 November 2027Patent 11033552*PED
  • 1 August 2028Patent 7579449 drug substance
  • 1 February 2029Patent 7579449*PED

15 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.